CLOs on the Move

New Health Sciences

www.newhealthsciences.com

 
New Health Sciences is developing Hemanext, a technology designed to improve the safety and efficacy of transfusion therapy through novel storage methods.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Westerner Park

Westerner Park is a Red Deer, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Certus Healthcare Management Consulting

Fort Lauderdale Home | Fort Lauderdale Health Care Consulting, Physician Practice Management and Hospitalist Management Consultant

R and J Engineering Corp

R & J Engineering Corp is a Kitchener, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Medizone International

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets, through its expanding distributor network. The AsepticSure® System is EPA-approved, received the CE mark and is currently pursuing FDA 510(k) registration.

Clinical ink

Clinical ink is the global life science company that brings data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.